Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Interest Income
Income earned on cash, deposits, and investments held by the company.
Sionna Therapeutics, Inc.NASDAQ: SION
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income dips below year-ago levels
Q1 FY2026 interest income of $2.82M fell 6.0% year over year, behind the +30.7% change in trailing-twelve-month interest income. Sequentially, it fell 11.1% from the prior quarter. Over 3 fiscal years it compounded at +127.3% a year.
Context
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.0% toward the trailing-twelve-month pace of +30.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 13.3M USD
- Year-over-year change
- +62.7%
- 3-year CAGR
- +127.3%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.3M | +62.7% |
| FY2024 | 2024-12-31 | 8.17M | +195.1% |
| FY2023 | 2023-12-31 | 2.77M | +144.6% |
| FY2022 | 2022-12-31 | 1.13M | — |
Interest Income vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 interest income of $13.12M is the 5th highest of the 11 companies compared; the peer median is $11.91M.
- Its year-over-year change of +30.7% is the 4th highest of 10, against a peer median of -6.9%.
- Over three fiscal years its annual growth of +127.3% compares with a peer median of +97.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $66.09M | +84.4% | +121.9% | 305.8% | |
| LTM Sep 2026 | $25.4M | -19.9% | +114.3% | 22679.5% | |
| LTM Jun 2026 | $22.96M | -6.9% | +140.9% | — | |
| LTM Sep 2026 | $18.04M | +57.2% | +1228.3% | — | |
| LTM Mar 2026 | $13.12M | +30.7% | +127.3% | — | |
| LTM Mar 2026 | $12.38M | +77.1% | +79.8% | 61.9% | |
| LTM Sep 2026 | $11.45M | -20.8% | +54.9% | 4.3% | |
| LTM Sep 2026 | $9.56M | -69.2% | +20.8% | 14.1% | |
| LTM Jun 2026 | $6.23M | -69.3% | — | — | |
| LTM Mar 2026 | $4.77M | +4.3% | +22.5% | 1.5% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SION) | $11.91M | -6.9% | +97.0% | 14.1% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.